CUSIP: G0750W203
Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
11,414,563
-
Share change
-
-522,299
-
Total reported value
-
$52,736,631
-
Put/Call ratio
-
157%
-
Price per share
-
$4.62
-
Number of holders
-
39
-
Value change
-
-$1,928,174
-
Number of buys
-
22
-
Number of sells
-
19
Quarterly Holders Quick Answers
What is CUSIP G0750W203?
CUSIP G0750W203 identifies AXGT - AXOVANT GENE THERAPIES LTD - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2020
-
Previous quarter:
Q2 2020
Recent filing periods for CUSIP G0750W203:
Institutional Holders of AXOVANT GENE THERAPIES LTD - COM (AXGT) as of Q3 2020
As of 30 Sep 2020,
AXOVANT GENE THERAPIES LTD - COM (AXGT) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,414,563 shares.
The largest 10 holders included
Consonance Capital Management LP, Opaleye Management Inc., Hudson Bay Capital Management LP, SPHERA FUNDS MANAGEMENT LTD., Corriente Advisors, LLC, Rubric Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and Ikarian Capital, LLC.
This page lists
39
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.